|
US2014358051A1
|
|
Method and device for scar management
|
|
AU2012201705A1
|
|
Nanoparticulate quinazoline derivative formulations
|
|
JP2012102131A
|
|
Prophylaxis and treatment for amyloidogenic disease
|
|
AU2011218610A1
|
|
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
|
WO2011146583A2
|
|
Nanoparticulate cinacalcet formulations
|
|
FR2945950A1
|
|
Anticancer nanoparticle compositions and methods for preparing the same
|
|
US2010297252A1
|
|
Nanoparticulate meloxicam formulations
|
|
CA2723998A1
|
|
Combination of a triptan and an nsaid
|
|
EP2268265A2
|
|
Compositions for site-specific delivery of imatinib and methods of use
|
|
MX2010009628A
|
|
Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens.
|
|
CA2713753A1
|
|
Alpha-synuclein kinase
|
|
WO2009099896A1
|
|
Thermal denaturation screening assay to identify candidate compounds for prevention and treatment of parkinson's disease
|
|
ZA200900186B
|
|
Nanoparticulate formulations of modafinil
|
|
EP2230906A1
|
|
Nanoparticulate anidulafungin compositions and methods for making the same
|
|
US2009155331A1
|
|
Injectable nanoparticulate olanzapine formulations
|
|
US2009104273A1
|
|
Novel nifedipine compositions
|
|
WO2010044803A1
|
|
Treatment of amyloidogenic diseases
|
|
US2009149479A1
|
|
Dosing regimen
|
|
EP2197448A1
|
|
Dosing regimen
|
|
US8017348B1
|
|
Assay for Parkinson's Disease therapeutics
|
